Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Myasthenia Gravis 2

Interventions

pembrolizumab 134Carboplatin 134Cisplatin 121Paclitaxel 105Gemcitabine 89Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 74Cyclophosphamide 61Dexamethasone 60Pemetrexed 58Bevacizumab 56durvalumab 55Capecitabine 55Doxorubicin 52Radiotherapy 51Oxaliplatin 50Fluorouracil 49Radiation 48Rituximab 44Leucovorin 44Vincristine 42Lenalidomide 41Etoposide 39atezolizumab 37Nivolumab 37Letrozole 36130-nm albumin-bound paclitaxel 33Prednisone 31Irinotecan 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × ravulizumab × 90 days × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

NCT05644561 2026-04-17

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
12 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡